China Universal Asset Management Company’s Maravai LifeSciences MRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$146K Sell
23,476
-2,501
-10% -$10.8K 0.01% 381
2026
Q1
$73.5K Buy
25,977
+2,346
+10% +$7.95K 0.01% 433
2025
Q4
$76.8K Sell
23,631
-1,729
-7% -$5.82K 0.01% 425
2025
Q3
$72.8K Sell
25,360
-3,557
-12% -$9.08K 0.01% 407
2025
Q2
$69.7K Buy
28,917
+466
+2% +$979 0.01% 392
2025
Q1
$62.9K Sell
28,451
-1,625
-5% -$6.42K 0.01% 396
2024
Q4
$164K Buy
30,076
+2,851
+10% +$18.3K 0.02% 341
2024
Q3
$226K Buy
27,225
+11,621
+74% +$100K 0.02% 293
2024
Q2
$112K Sell
15,604
-9,830
-39% -$84.9K 0.02% 294
2024
Q1
$221K Buy
25,434
+10,142
+66% +$68.6K 0.03% 277
2023
Q4
$100K Buy
15,292
+11,901
+351% +$76.9K 0.02% 278
2023
Q3
$33.9K Buy
3,391
+1,662
+96% +$18.3K 0.01% 256
2023
Q2
$21.5K Sell
1,729
-57
-3% -$769 0.01% 261
2023
Q1
$25K Buy
1,786
+450
+34% +$6.46K 0.01% 200
2022
Q4
$19.1K Buy
1,336
+104
+8% +$1.64K 0.01% 176
2022
Q3
$31K Buy
+1,232
New +$30.9K 0.01% 138

Other funds holding MRVI

China Universal Asset Management Company's MRVI Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Maravai LifeSciences (MRVI) stake by 9.6% in Q2 2026, selling an estimated $10.8K and leaving 23,476 shares worth $146K. The position accounts for 0.01% of the portfolio, ranked #381.

China Universal Asset Management Company first reported a position in MRVI in Q3 2022 and has held it in 16 quarters since. The position peaked at $226K in Q3 2024. 20 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • China Universal Asset Management Company held 23,476 shares of Maravai LifeSciences worth $146K as of Q2 2026.
  • China Universal Asset Management Company sold 2,501 Maravai LifeSciences shares in Q2 2026, an estimated $10.8K.
  • Maravai LifeSciences made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #381 holding.
  • China Universal Asset Management Company first reported a position in Maravai LifeSciences in Q3 2022 and has held it in 16 quarters since.
  • China Universal Asset Management Company's Maravai LifeSciences position peaked at $226K in Q3 2024.
  • 20 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.